Cancer

First Patient Enrolled in Teleflex’s Barrigel™ Rectal Spacer Trial for Post Radical Prostatectomy Radiation Therapy (PPRT)

Randomized, controlled study will be first in personalized spacing evidence to include patients who have a prostate cancer recurrence after…

1 year ago

Medigene to Present at Upcoming Investor Conferences

Planegg/Martinsried, October 29, 2024. Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard), an oncology platform company focused on…

1 year ago

BioNxt Announces National Level Patent Filings for Sublingual Anticancer Drugs for the Treatment of Autoimmune Neurodegenerative Diseases

VANCOUVER, BC / ACCESSWIRE / October 29, 2024 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTC PINK:BNXTF)(FSE:BXT) is pleased…

1 year ago

Fountain Life Develops “Zora AI,” the World’s First Generative AI Platform Specially Trained in Functional and Longevity Medicine

LAKE NONA, Fla., Oct. 28, 2024 /PRNewswire/ -- Fountain Life, a company that offers longevity, preventative health, advanced diagnostics, and…

1 year ago

Cantargia Reports New Results from Clinical Studies Investigating Nadunolimab in Several Forms of Cancer; Supporting Ongoing Strategies

LUND, SE / ACCESSWIRE / October 28, 2024 / Cantargia (STO:CANTA) Cantargia (Cantargia AB); (Nasdaq Stockholm:CANTA) today announced new clinical…

1 year ago

CBIH Strengthens Competitive Advantage with Rapid Expansion of Patent Filings

Houston, Texas--(Newsfile Corp. - October 28, 2024) - Cannabis Bioscience International Holdings (OTC Pink: CBIH) trading on the OTC Markets under the…

1 year ago

CureVac to Present at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting

TÜBINGEN, GERMANY and BOSTON, MA / ACCESSWIRE / October 28, 2024 / CureVac N.V. (Nasdaq:CVAC) ("CureVac"), a global biopharmaceutical company…

1 year ago

MIRA Pharmaceuticals’ Ketamir-2 Shows 60% Greater Efficacy Than FDA-Approved Gabapentin in Reversing Chemotherapy-Induced Neuropathic Pain

Promising Preclinical Results Position Ketamir-2 as a Potential Breakthrough Therapy That Surpasses Current Treatments, With Results to Be Presented at…

1 year ago

Immunophotonics to Present at the 2024 ThinkEquity Conference

ST. LOUIS, Oct. 28, 2024 (GLOBE NEWSWIRE) -- Immunophotonics, Inc. a clinical-stage biotech company focused on the discovery and development…

1 year ago

Lisata Therapeutics Announces Sponsored Preclinical Research Agreement with the University of Cincinnati to Study Certepetide for the Treatment of Endometriosis

Strategic partnership explores therapeutic effect of Lisata’s novel cyclic peptide product candidate, certepetide, in combination with bevacizumabBASKING RIDGE, N.J., Oct.…

1 year ago